Administer revised earnings guidance for the full year 2022. For the period, the company expected net sales to be EUR 47 million to EUR 49 million compared to previously expected net sales to be EUR 51 million. Administer lowers its outlook for net sales and EBITDA margin for 2022 as the increased general economic uncertainty has impacted customer activity.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.5 EUR | 0.00% | 0.00% | +3.73% |
Apr. 22 | BioXcel Therapeutics to Launch At-Home Trial of Potential Bipolar, Schizophrenia Agitation Treatment | MT |
Apr. 11 | Gerresheimer shares down on outlook, but key contracts confirmed | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.73% | 38.43M | |
-12.82% | 286M | |
-.--% | 62.2M | |
-19.85% | 59.48M |
- Stock Market
- Equities
- ADMIN Stock
- News Administer Oyj
- Administer Revises Earnings Guidance for the Full Year 2022